AGIO
Agios Pharmaceuticals, Inc.
NASDAQ · USHealthcareBiotechnology
$40.06+1.14%
Price as of Jul 20, 2026
AGIO growth
Agios Pharmaceuticals, Inc. growth
Reported trailing growth, forward expectations and three-year compound growth rates.
Trailing growth
Year over year
- Revenue
- +78.3%
- EBITDA
- -0.2%
- EBIT
- -8.0%
- EPS
- —
- Free cash flow
- +4.7%
- Operating cash flow
- +5.2%
Forward estimates
- Revenue
- -12.2%
- EBITDA
- +91.7%
- EPS
- +58.6%
Three-year CAGR
- Revenue
- +56.0%
- EBITDA
- —
- EBIT
- -10.9%
- Net income
- —
- EPS
- —
- Free cash flow
- +3.6%
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.